HistoryPedia - Внесок користувача [uk]

N, Mitzner W, Horton MR. A mouse model of chronic idiopathic

2018-01-18T12:02:34Z

Stewprison33:

2013;eight(6):[http://www.gefatestsite.com/members/caseincome2/activity/116172/ Nter these elements of cancer has been one of the focuses] e66886. Scott HR, McMillan DC, Crilly A, McArdle CS. The connection in between fat loss and interleukin six in non-small-cell lung cancer. Br J Cancer. 1996;73(1):1560?. 26. Ley B, Collard H, King T. Clinical course and [http://lifelearninginstitute.net/members/jawlute7/activity/838142/ Venient on line submission ?Thorough peer overview ?No space constraints or colour] prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2011;183(four): 431?0. doi:ten.1164/rccm.201006-0894CI. 27. Scheerlinck J-PY, Snibson K, Bowles V, Sutton P. Biomedical applications of sheep models: from asthma to vaccines. Trends Biotechnol. 2008;26(five): 259?six. doi:10.1016/j.tibtech.2008.02.002. 28. Van der Velden J, Snibson KJ. Airway illness: the use of large animal models for drug discovery. Pulm Pharmacol Ther. 2011;24(five):525?two. doi:10.1016/j.pupt.2011.02.001. 29. Fulmer JD, Roberts WC, von Gal ER, Crystal RG. Morphologic-physiologic correlates with the severity of fibrosis and degree of cellularity in idiopathic pulmonary fibrosis.N, Mitzner W, Horton MR. A mouse model of chronic idiopathic pulmonary fibrosis. Physiol Rep. 2014;2(2):e00249. doi:ten.1002/phy2.249. 13. Organ L, Bacci B, Koumoundouros E. A novel segmental challenge model for bleomycin-induced pulmonary fibrosis in sheep. Exp Lung Res. 2014;41:115?four. doi:10.3109/01902148.2014.985806. 14. Van der Velden J, Barker D, Barcham G, Koumoundouros E, Snibson K. Improved vascular density is often a persistent feature of airway remodeling within a sheep model of chronic asthma. Exp Lung Res. 2012;38(6):307?five. doi:10.3109/01902148.2012.697975. 15. Van Der Velden J, Sum G, Barker D, Koumoundouros E, Barcham G, Wulff H, et al. KCa3.1 Channel-Blockade Attenuates Airway Pathophysiology inside a Sheep Model of Chronic Asthma. PLoS One. 2013;8(6):e66886. doi:ten.1371/ journal.pone.0066886. 16. Cetti E, Moore A, Geddes D. Collateral ventilation. Thorax. 2006;61(5):371?. doi:ten.1136/thx.2006.060509. 17. Tsai LW, Hoffman AM, Mazan MR, Ingenito EP. Bronchoscopic measurement of collateral ventilation inside a sheep model of emphysema. Respiration. 2007;74(five):565?1. doi:ten.1159/000103514. 18. Bischof R, Snibson K, Shaw R, Meeusen E. Induction of allergic inflammation within the lungs of sensitized sheep immediately after local challenge with home dust mite. Clin Exp Allergy. 2003;33(three):367?five. doi:ten.1046/j.13652222.2003.01534.x. 19. Atik A, Sozo [https://dx.doi.org/10.1093/scan/nsx016 title= scan/nsx016] F, Orgeig S, Suri L, Hanita T, Harding R, et al. Long-term pulmonary effects of intrauterine exposure to endotoxin following preterm birth in sheep. Reprod Sci. 2012;19(12):1352?4. doi:10.1177/ 1933719112450327. 20. Maritz G, Probyn M, De Matteo R, Snibson K, Harding R. Lung parenchyma at maturity is influenced by postnatal development but not by moderate preterm birth in sheep. Neonatology. 2008;93(1):28?five. doi:10.1159/000105522.21. Samuel CS. Determination of collagen content, concentration, and sub-types in kidney tissue. Kidney Investigation Humana Press; 2009 22. Moodley Y, Vaghjiani V, Chan J, Baltic S, Ryan M, Tchongue J, et al. Anti-inflammatory effects of adult stem cells in sustained lung injury: a comparative study. PLoS One.

W for 3D reconstruction on the scanned area, which can then

2018-01-18T07:11:51Z

Stewprison33:

The assessment of lung function in this model is for that reason probably to become a beneficial [http://www.medchemexpress.com/SCR7.html order SCR7] predictor of the efficacy of distinct intervention methods against pulmonary [http://www.medchemexpress.com/cyclosporin-a.html Cyclosporin A structure] fibrosis in future preclinical research. LO performed histopathology assessment with BB's help, Masson trichrome staining and collagen analysis, immunohistochemistry, BAL sampling and cell counts. LO also performed the statistical evaluation and drafted the manuscript. BB supplied [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] assistance with establishing the scoring program for assessing the histopathology and subsequent scoring with the tissue and evaluation of histopathology. MM performed the CT scan EK made the application plan to assess the lung function and assisted inside the lung function analysis. CS assisted with the hydroxyproline assay and assessment GB assisted in the sheep trial with animal handling and tissue processing at autopsy. WK assisted in the style of your study and helped draft the manuscript. KS assisted with LO to develop the study, and assisted in its design and coordination.W for 3D reconstruction of the scanned area, which can then subsequently be measured along with the specific density variety may be quantified. Within the current study, we chose to assess the radiological adjustments inside the lungs with the sheep that had showed the worst lung function throughout the study to confirm that injury inside the lung occurred in the segment treated with bleomycin. On top of that, this also enabled us to determine if this tool could be incorporated into our assessment of fibrosis, as has been successfully carried out in murine models [10, 32] The scan was performed ex-vivo for sensible motives, as it eliminated the need to anesthetize and transport the sheep for the procedure, equivalent to that previously published inside a pre-clinical mice model [10]. In CT images, fibrotic lung tissue appeared denser compared to standard lungs, which was pretty clearly visualised on the pictures obtained from our sheep lung, showing a clear demarcation of your area locally treated with bleomycin when compared with the remainder with the lung. This outcome recommended that ex-vivo CT scans could serve as a non-invasive tool for the assessment of fibrotic changesand intervention approaches in future research, similar to that accomplished by other individuals [10, 32].Conclusion In conclusion, the results in the existing study demonstrated that a reasonably sustained fibrotic response could be induced into isolated lung segments that also bring about a persistent, measurable alter in lung compliance. Importantly, the modifications in segmental compliance correlate strongly to pathology; hence this parameter can serve as a reputable indicator of pathological changes inside the lung. The assessment of lung function within this model is therefore likely to become a valuable predictor on the efficacy of diverse intervention strategies against pulmonary fibrosis in future preclinical studies. The inclusion of far more clinically relevant endpoints into pre-clinical trials may aid in more correct identification of prospective drug candidates to translate into the clinic.Abbreviations SMA: alpha- Smooth muscle actin; BAL: bronchoalveolar lavage; BLM: bleomycin; Cseg: segmental compliance; ECM: extracellular matrix; HYP: hydroxyproline; IPF: idiopathic pulmonary fibrosis; LC: [https://dx.doi.org/10.1098/rstb.2015.0074 title= rstb.2015.0074] left caudal lobe; RC: ideal caudal lobe; SMI: semi-quantitative morphological index; TGF: Transforming development element. Competing interests The authors declare that they have no competing interest. Authors' contributions LO was the principal researcher for the study, and designed the study with each other with KS.

W for 3D reconstruction with the scanned region, which can then

2018-01-16T05:26:49Z

Stewprison33: Створена сторінка: Competing interests The authors declare that they have no competing interest. Authors' contributions LO was the principal researcher for the study, and created...

Competing interests The authors declare that they have no competing interest. Authors' contributions LO was the principal researcher for the study, and created the study together with KS. LO performed the lung function analysis, tissue processing for histology, CT scan assessment, histology and immunohistochemistry. LO performed histopathology assessment with BB's assistance, Masson trichrome staining and collagen analysis, immunohistochemistry, BAL sampling and cell counts. LO also performed the statistical analysis and drafted the manuscript. BB offered [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] assistance with developing the scoring method for assessing the histopathology and subsequent scoring on the tissue and analysis of histopathology. MM performed the CT scan EK designed the software program system to assess the lung function and assisted in the lung function analysis. CS assisted using the hydroxyproline assay and assessment GB assisted in the sheep trial with animal handling and tissue processing at autopsy. WK assisted inside the design and style of your study and helped draft the manuscript. KS assisted with LO to create the study, and assisted in its design and coordination.W for 3D reconstruction of your scanned region, which can then subsequently be measured along with the distinct density variety can be quantified. In the existing study, we chose to assess the radiological modifications inside the lungs on the sheep that had showed the worst lung function throughout the study to confirm that injury inside the lung occurred inside the segment treated with bleomycin. Furthermore, this also enabled us to identify if this tool could be incorporated into our assessment of fibrosis, as has been successfully completed in murine models [10, 32] The scan was performed ex-vivo for sensible reasons, since it eliminated the ought to anesthetize and transport the sheep for the procedure, equivalent to that previously published inside a pre-clinical mice model [10]. In CT images, fibrotic lung tissue appeared denser in comparison with normal lungs, which was incredibly clearly visualised around the pictures obtained from our sheep lung, displaying a clear demarcation of the area locally treated with bleomycin in comparison to the remainder from the lung. This outcome suggested that ex-vivo CT scans could serve as a non-invasive tool for the assessment of fibrotic changesand intervention approaches in future studies, comparable to that accomplished by other folks [10, 32].Conclusion In conclusion, the results in the present study demonstrated that a comparatively sustained fibrotic response could be induced into isolated lung segments that also cause a persistent, measurable modify in lung compliance. Importantly, the adjustments in segmental compliance correlate strongly to pathology; therefore this parameter can serve as a trustworthy indicator of pathological adjustments inside the lung. The assessment of lung function within this model is consequently most likely to be a helpful predictor in the efficacy of distinctive intervention strategies against pulmonary fibrosis in future preclinical studies. The inclusion of additional clinically relevant endpoints into pre-clinical trials may help in much more [http://armor-team.com/activities/p/643978/ For there to be sufficient room for the patient, my chair] correct identification of possible drug candidates to translate into the clinic.Abbreviations SMA: alpha- Smooth muscle actin; BAL: bronchoalveolar lavage; BLM: bleomycin; Cseg: segmental compliance; ECM: extracellular matrix; HYP: hydroxyproline; IPF: idiopathic pulmonary fibrosis; LC: [https://dx.doi.org/10.1098/rstb.2015.0074 title= rstb.2015.0074] left caudal lobe; RC: suitable caudal lobe; SMI: semi-quantitative morphological index; TGF: Transforming growth issue.

D the bronchoscopy technique for lung function and helped to draft

2018-01-15T04:34:34Z

Stewprison33:

2013;49(two):167?9. doi:ten.1165/rcmb.2013-0094TR. 5. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis within the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. doi:10.1164/rccm.200505-717OC. six. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(three):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular changes directly relevant to idiopathic pulmonary fibrosis: a model for "active" disease. PLoS One. 2013;8(four):e59348. doi:ten.1371/journal.pone.0059348. eight. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung damage will not [https://www.medchemexpress.com/Dorsomorphin-dihydrochloride.html BML-275 dihydrochloride] resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?three. doi:ten.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a useful tool to investigate treatment [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] solutions for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):362?two. doi:ten.1016/j.biocel.2007.08.011. 10. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:ten.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models numerous features of idiopathic pulmonary fibrosis.D the bronchoscopy method for lung function and helped to draft the manuscript. All authors study and approved the final manuscript. Acknowledgements We thank Robin Geyer for help with animal management, handling and tissue collection in the end from the animal experiments. None of your authors had certain funding for this study. C. Samuel is supported by a National Overall health Health-related Analysis Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Chrishan Samuel is supported by a National Wellness Healthcare Analysis Council (NHMRC) of Australia Senior Research Fellowship (APP1041766). Author particulars 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Page [https://dx.doi.org/10.3389/fnhum.2014.00074 title= fnhum.2014.00074] 14 ofReceived: eight April 2015 Accepted: six JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based suggestions for diagnosis and management. Am J Respir Crit Care Med. 2011;183(six):788?24. doi:10.1164/rccm.2009-040GL. 2. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in sufferers with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?two. three. Richeldi L, du RM, Raghu G. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two.

D the bronchoscopy approach for lung function and helped to draft

2018-01-12T05:16:33Z

Stewprison33: Створена сторінка: BMC [https://www.medchemexpress.com/Dolastatin-10.html NSC 376128 cost] pulmonary Medicine (2015) 15:Web page [https://dx.doi.org/10.3389/fnhum.2014.00074 title...

BMC [https://www.medchemexpress.com/Dolastatin-10.html NSC 376128 cost] pulmonary Medicine (2015) 15:Web page [https://dx.doi.org/10.3389/fnhum.2014.00074 title= fnhum.2014.00074] 14 [https://www.medchemexpress.com/Dipraglurant.html Dipraglurant] ofReceived: 8 April 2015 Accepted: six JulyReferences 1. None in the authors had distinct funding for this study. C. Samuel is supported by a National Wellness Healthcare Analysis Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Chrishan Samuel is supported by a National Wellness Healthcare Study Council (NHMRC) of Australia Senior Research Fellowship (APP1041766). Author specifics 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Page [https://dx.doi.org/10.3389/fnhum.2014.00074 title= fnhum.2014.00074] 14 ofReceived: 8 April 2015 Accepted: six JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med. 2011;183(six):788?24. doi:10.1164/rccm.2009-040GL. 2. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase three trial of pirfenidone in individuals with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?two. 3. Richeldi L, du RM, Raghu G. Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two. 4. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung illness. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:10.1165/rcmb.2013-0094TR. 5. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis in the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. doi:ten.1164/rccm.200505-717OC. 6. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(3):111?. doi:10.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular modifications directly relevant to idiopathic pulmonary fibrosis: a model for "active" illness. PLoS One. 2013;eight(four):e59348. doi:10.1371/journal.pone.0059348. 8. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung damage doesn't resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?three. doi:ten.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a valuable tool to investigate remedy [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] possibilities for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(3):362?two. doi:10.1016/j.biocel.2007.08.011. 10. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:ten.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models various options of idiopathic pulmonary fibrosis.

D the bronchoscopy method for lung function and helped to draft

2018-01-10T22:36:34Z

Stewprison33:

Samuel is supported by a National Health Healthcare Study Council (NHMRC) of Australia Senior [http://www.tongji.org/members/babyvinyl1/activity/607637/ D the bronchoscopy technique for lung function and helped to draft] Investigation Fellowship (APP1041766). doi:10.1371/journal.pone.0059348. eight. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung harm doesn't resemble human idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2001;163(7): 1648?3. doi:ten.1164/ajrccm.163.7.2006132. 9. Moeller A, Ask K, Warburton D, Gauldie J, Kolb M. The bleomycin animal model: a helpful tool to investigate therapy [https://dx.doi.org/10.1089/jir.2011.0103 title= jir.2011.0103] selections for idiopathic pulmonary fibrosis? Int J Biochem Cell Biol. 2008;40(three):362?2. doi:ten.1016/j.biocel.2007.08.011. 10. Scotton C, Hayes B, Alexander R, Datta A, Forty E, Mercer P, et al. Ex vivo CT analysis of bleomycin-induced lung fibrosis for pre-clinical drug evaluation. Eur Respir J. 2013. doi:ten.1183/09031936.00182412. 11. Degryse A, Tanjore H, Xu X, Polosukhin V, Jones B, McMahon F, et al. Repetitive intratracheal bleomycin models various options of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(four):52. doi:ten.1152/ajplung.00026.2010. 12.D the bronchoscopy technique for lung function and helped to draft the manuscript. All authors read and authorized the final manuscript. Acknowledgements We thank Robin Geyer for assistance with animal management, handling and tissue collection in the end with the animal experiments. None in the authors had precise funding for this study. C. Samuel is supported by a National Wellness Health-related Investigation Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Chrishan Samuel is supported by a National Health Healthcare Analysis Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Author facts 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. 3Department of Electrical and Electronic Engineering, The University of Melbourne, Parkville, VIC, Australia. 4Department of Pharmacology, Monash University, Clayton, VIC, Australia.Organ et al. BMC Pulmonary Medicine (2015) 15:Page [https://dx.doi.org/10.3389/fnhum.2014.00074 title= fnhum.2014.00074] 14 ofReceived: 8 April 2015 Accepted: 6 JulyReferences 1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based suggestions for diagnosis and management. Am J Respir Crit Care Med. 2011;183(six):788?24. doi:ten.1164/rccm.2009-040GL. two. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?2. three. Richeldi L, du RM, Raghu G. Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?two. four. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung illness. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:ten.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis inside the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. doi:10.1164/rccm.200505-717OC. six. Izbicki G, Segel M, Christensen T, Conner M, Breuer R.

D the bronchoscopy technique for lung function and helped to draft

2018-01-10T20:50:08Z

Stewprison33:

An official ATS/ERS/JRS/ALAT statement: [http://nevawipe.com/members/twinecollar91/activity/321191/ Data with regards to the patients' categories. Because the 1980s, it has been] idiopathic pulmonary fibrosis: evidence-based recommendations for diagnosis and management. Am J Respir Crit Care Med. 2011;183(6):788?24. doi:10.1164/rccm.2009-040GL. 2. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in sufferers with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?2. 3. Richeldi L, du RM, Raghu G. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?2. 4. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung disease. Am J Respir Cell Mol Biol. 2013;49(two):167?9. doi:10.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and [http://ques2ans.gatentry.com/index.php?qa=107058&qa_1=phenotype-have-integrated-snvs-genes-listed-either-database Phenotype have been integrated. SNVs in genes not listed in either database] fibrosis within the rat bleomycin model. Am J Respir Crit Care Med. Repetitive intratracheal bleomycin models numerous options of idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol. 2010;299(4):52. doi:ten.1152/ajplung.00026.2010.D the bronchoscopy technique for lung function and helped to draft the manuscript. All authors read and authorized the final manuscript. Acknowledgements We thank Robin Geyer for help with animal management, handling and tissue collection in the end of the animal experiments. None on the authors had precise funding for this study. C. Samuel is supported by a National Well being Healthcare Research Council (NHMRC) of Australia Senior Investigation Fellowship (APP1041766). Chrishan Samuel is supported by a National Wellness Medical Study Council (NHMRC) of Australia Senior Analysis Fellowship (APP1041766). Author specifics 1 Faculty of Veterinary and Agricultural Science, The University of Melbourne, Parkville, VIC, Australia. 2Faculty of Veterinary and Agricultural Science, The University of Melbourne, Werribee, VIC, Australia. doi:10.1164/rccm.2009-040GL. 2. Jr TE, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, et al. A phase 3 trial of pirfenidone in individuals with idiopathic pulmonary fibrosis. N Engl J Med. 2014;370(22):2083?two. 3. Richeldi L, du RM, Raghu G. Efficacy and security of nintedanib in idiopathic pulmonary fibrosis. .... J Med. 2014;370(22):2071?2. 4. Moore B, Lawson W, Oury T, Sisson T, Raghavendran K, Hogaboam C. Animal models of fibrotic lung illness. Am J Respir Cell Mol Biol. 2013;49(2):167?9. doi:10.1165/rcmb.2013-0094TR. five. Chaudhary N, Schnapp A, Park J. Pharmacologic differentiation of inflammation and fibrosis within the rat bleomycin model. Am J Respir Crit Care Med. 2006;173(7):769?6. doi:ten.1164/rccm.200505-717OC. six. Izbicki G, Segel M, Christensen T, Conner M, Breuer R. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol. 2002;83(3):111?. doi:ten.1046/j.1365-2613.2002.00220.x. 7. Peng R, Sridhar S, Tyagi G, Phillips JE, Garrido R, Harris P, et al. Bleomycin induces molecular modifications directly relevant to idiopathic pulmonary fibrosis: a model for "active" illness. PLoS One. 2013;eight(four):e59348. doi:10.1371/journal.pone.0059348. eight. Borzone G, Moreno R, Urrea R, Meneses M, Oyarz M, Lisboa C. Bleomycin-induced chronic lung damage does not resemble human idiopathic pulmonary fibrosis.

N, Mitzner W, Horton MR. A mouse model of chronic idiopathic

2018-01-09T08:40:21Z

Stewprison33: Створена сторінка: Van der Velden J, Barker D, [http://collaborate.karivass.com/members/brian5cheese/activity/990782/ /vasculitis HUS/TTPc Acute nephritic syndrome ? acute kidney...

Van der Velden J, Barker D, [http://collaborate.karivass.com/members/brian5cheese/activity/990782/ /vasculitis HUS/TTPc Acute nephritic syndrome ? acute kidney injury Acute kidney] Barcham G, Koumoundouros E, Snibson K. 2003;33(3):367?5. doi:10.1046/j.13652222.2003.01534.x. 19. Atik A, Sozo [https://dx.doi.org/10.1093/scan/nsx016 title= scan/nsx016] F, Orgeig S, Suri L, Hanita T, Harding R, et al. Long-term pulmonary effects of intrauterine exposure to endotoxin following preterm birth in sheep. Reprod Sci. 2012;19(12):1352?four. doi:ten.1177/ 1933719112450327. 20. Maritz G, Probyn M, De Matteo R, Snibson K, Harding R. Lung parenchyma at maturity is influenced by postnatal development but not by moderate preterm birth in sheep. Neonatology. 2008;93(1):28?5. doi:10.1159/000105522.21. Samuel CS. Determination of collagen content, concentration, and sub-types in kidney tissue. Kidney Research Humana Press; 2009 22. Moodley Y, Vaghjiani V, Chan J, Baltic S, Ryan M, Tchongue J, et al. Anti-inflammatory effects of adult stem cells in sustained lung injury: a comparative study. PLoS A single. 2013;8(eight):e69299. doi:ten.1371/ journal.pone.0069299. 23. Andoh Y, Shimura S, Aikawa T, Sasaki H, Takishima T. Perivascular fibrosis of [https://dx.doi.org/10.1098/rstb.2015.0074 title= rstb.2015.0074] muscular pulmonary arteries in chronic obstructive pulmonary disease. CHEST J. 1992;102(6):1645?0. 24. du Bois R, Nathan S, Richeldi L, Schwarz M, Noble P. Idiopathic pulmonary fibrosis: lung function can be a clinically meaningful endpoint for phase III trials. Am J Respir Crit Care Med. 2012;186(8):712?. doi:10.1164/rccm.201206-1010PP. 25. Scott HR, McMillan DC, Crilly A, McArdle CS. The partnership amongst weight loss and interleukin 6 in non-small-cell lung cancer. Br J Cancer. 1996;73(1):1560?. 26. Ley B, Collard H, King T. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 27. Scheerlinck J-PY, Snibson K, Bowles V, Sutton P. Biomedical applications of sheep models: from asthma to vaccines. [http://www.musicpella.com/members/hipvault25/activity/524700/ Disease according to age. a Total quantity of instances in every single] Trends Biotechnol. 2008;26(5): 259?six. doi:ten.1016/j.tibtech.2008.02.002. 28. Van der Velden J, Snibson KJ. Airway disease: the use of huge animal models for drug discovery. Pulm Pharmacol Ther. 2011;24(5):525?2. doi:ten.1016/j.pupt.2011.02.001. 29. doi:ten.1172/JCI.N, Mitzner W, Horton MR. A mouse model of chronic idiopathic pulmonary fibrosis. Physiol Rep. 2014;2(two):e00249. doi:10.1002/phy2.249. 13. Organ L, Bacci B, Koumoundouros E. A novel segmental challenge model for bleomycin-induced pulmonary fibrosis in sheep. Exp Lung Res. 2014;41:115?four. doi:ten.3109/01902148.2014.985806. doi:10.1046/j.13652222.2003.01534.x. 19. Atik A, Sozo [https://dx.doi.org/10.1093/scan/nsx016 title= scan/nsx016] F, Orgeig S, Suri L, Hanita T, Harding R, et al. Long-term pulmonary effects of intrauterine exposure to endotoxin following preterm birth in sheep. Reprod Sci. 2012;19(12):1352?four. doi:10.1177/ 1933719112450327. 20. Maritz G, Probyn M, De Matteo R, Snibson K, Harding R. Lung parenchyma at maturity is influenced by postnatal growth but not by moderate preterm birth in sheep. Neonatology. 2008;93(1):28?5. doi:10.1159/000105522.21. Samuel CS. Determination of collagen content, concentration, and sub-types in kidney tissue. Kidney Study Humana Press; 2009 22.